Drug Profile
Iptacopan - Novartis Pharmaceuticals
Alternative Names: FABHALTA; Iptacopan hydrochloride monohydrate - Novartis Pharmaceuticals; LNP 023; LNP023-AAB; NVP-LNP023; NVP-LNP023-AAB; NVP-LNP023-NXLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Novartis Pharmaceuticals
- Class Anti-inflammatories; Antianaemics; Benzoic acids; Ethers; Eye disorder therapies; Indoles; Piperidines; Small molecules; Urologics
- Mechanism of Action Complement factor B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Paroxysmal nocturnal haemoglobinuria
- Phase III Atypical Haemolytic Uraemic Syndrome; IgA nephropathy; Membranoproliferative glomerulonephritis
- Phase II Age-related macular degeneration; Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura; Lupus nephritis; Membranous glomerulonephritis
Most Recent Events
- 22 Mar 2024 CHMP recommends positive opinion of Iptacopan for Paroxysmal nocturnal hemoglobinuria in European Union
- 20 Dec 2023 Launched for Paroxysmal nocturnal haemoglobinuria in USA (PO) - First global launch
- 11 Dec 2023 Efficacy and adverse events data from a phase III APPEAR-C3G trial in membranoproliferative glomerulonephritis released by Novartis Pharmaceuticals